Urogen's Chief Medical Officer Insider Trade: 400K Sale Insights
A high-profile insider sale at UroGen Pharma raises questions about market signals and biotech risk. This article unp...
In 2024, comparing Itot and Vti costs helps identify the more economical choice for long-term retirement goals.
28,280 articlesA high-profile insider sale at UroGen Pharma raises questions about market signals and biotech risk. This article unp...
Broadcom is edging toward a 52-week peak as AI demand fuels revenue growth and capital returns. Analysts weigh buy, h...
Citigroup is up about 14% year-to-date through mid-July 2026, outpacing Bank of America and Wells Fargo. AI-driven tr...
As AI workloads surge, hyperscalers turn to ASICs to cut costs. This deep dive compares Broadcom and Marvell, explain...
SpaceX is trading far above its IPO price. This article explains what that gain means for early investors, what could...
One rental property changed everything for a seasoned investor. This article reveals the smart loans, disciplined hab...
As AI and data demand surge, investors eye NuScale Power and the small modular reactor trend. Can nuscale power next ...
Investors chasing quantum headlines often overlook how a big subscription software player can deliver durable AI-and-...
As 2025 unfolds, MediWound faces a pivotal year for debt, cash, and milestones. This analysis breaks down what mediwo...
Could this clean tech stock turn a modest investment into a life-changing fortune? This guide demystifies the path to...
A boutique fund revealed a sizable stake in a hotel stock, signaling interest in the sector’s recovery. Here’s a prac...
A loose, little-regulated lending network is stepping in to help small businesses cover tariffs quickly, but with ste...